Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,271,987.22 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 218,041 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the sale, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,345,374.98. This trade represents a 19.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Eric Venker also recently made the following trade(s):

• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00.

Roivant Sciences Stock Performance

Shares of ROIV stock opened at $10.56 on Monday. The firm has a market cap of $7.69 billion, a P/E ratio of 1.87 and a beta of 1.25. The business’s 50 day moving average price is $11.34 and its 200-day moving average price is $11.59. Roivant Sciences Ltd. has a fifty-two week low of $9.76 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. As a group, equities analysts predict that Roivant Sciences Ltd. will post -1.19 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ROIV. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $18.08.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after acquiring an additional 1,948 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Roivant Sciences in the 3rd quarter worth approximately $35,000. US Bancorp DE lifted its stake in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in shares of Roivant Sciences during the fourth quarter valued at approximately $39,000. Finally, GAMMA Investing LLC grew its stake in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.